Aclerastide

Aclerastide is an angiotensin receptor agonist. It can reduce fibrosis and scarring in the healing wounds. This action is more pronounced with longer administration of the peptide after injury. The action of this peptide is blocked by the AT receptor antagonist d-Ala7-angiotensin(1-7), which suggests that this receptor is involved in the healing responses to exogenous NorLeu3-A(1-7). Aclerastide has the potential in accelerating wound repair and reducing scar formation.

Online Inquiry

Specification Technical Data Related Products Customer reviews and Q&A Useful Tools Publications

CAT#	10-101-183
CAS	227803-63-6
Background	Aclerastide, also known as DSC-127; NorLeu-3-A (1-7); NorLeu-3A (1-7), is an angiotensin receptor agonist potentially for the treatment of tissue regeneration in diabetic ulcers. Administration of NorLeu3-A (1-7) reduced fibrosis and scarring in the healing wounds. This action was more pronounced with longer administration of the peptide after injury. The action of this peptide was blocked by the AT receptor antagonist d-Ala7-angiotensin (1-7), which suggests that this receptor is involved in the healing responses to exogenous NorLeu3-A (1-7). Aclerastide may have the potential in accelerating wound repair and reducing scar formation. Aclerastide has been investigated for the treatment of Diabetic Foot, Diabetic Foot Ulcers, and Foot Ulcer, Diabetic. >> Read More
Synonyms/Alias	Norleu3-a(1-7); UNII-YYD6UT8T47; Asp-arg-nle-tyr-ile-his-pro; DSC127; DSC-127; USB-001;
M.F/Formula	C42-H64-N12-O11
M.W/Mr.	913.0406
Sequence	H-Asp-Arg-Nle-Tyr-Ile-His-Pro-OH
Labeling Target	Angiotensin receptor
Application	Aclerastide is studied for the treatment of Diabetic Foot, Diabetic Foot Ulcers, and Foot Ulcer, Diabetic.
Appearance	Solid powder
Purity	>98% (or refer to the Certificate of Analysis)
Activity	Agonist
Biological Activity	Aclerastide, also known as DSC-127; NorLeu-3-A(1-7); NorLeu-3A(1-7), is an angiotensin receptor agonist potentially for the treatment of tissue regeneration in diabetic ulcers.
Areas of Interest	Diabetic Foot, Diabetic Foot Ulcers, and Foot Ulcer, Diabeti
Target	Angiotensin Receptor

CAT#	Product Name	M.W	Molecular Formula	Inquiry
10-101-158	Albiglutide	72970.4029	C3232H5032N864O979S41	Inquiry
10-101-18	Glucagon	3482.8	C153H225N43O49S	Inquiry
10-101-59	Liraglutide	3751.2	C172H265N43O51	Inquiry

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Source#	Synthetic
Storage	-20°C
Solubility	Soluble in DMSO
Shipping Condition	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Short-term Storage Conditions	Dry, dark and at 0 - 4 °C
Long-term Storage Conditions	-20 °C
ShelfLife	>2 years if stored properly
References	Preclinical and clinical research shows that DSC127 is highly effective in the closure of diabetic wounds and is superior to Regranex in animal studies. Clinical development of DSC127 as a topical agent for the healing of DFU is underway. Further investigation into the mechanisms by which this product accelerates healing is warranted. NorLeu3-Angiotensin (1-7) [DSC127] as a Therapy for the Healing of Diabetic Foot Ulcers Derma Sciences, a tissue regeneration company focused on advanced wound and burn care, announced the termination of its Phase III clinical trials with aclerastide (DSC 127) for diabetic foot ulcer healing. This action is based on futility determinations conducted by the Data Monitoring Committee (DMC) for the planned, pre-specified interim analyses regarding the primary efficacy endpoint of confirmed complete wound closure of the target ulcer within 12 weeks of the start of treatment. DSC 127 (aclerastide) fails diabetic foot ulcer healing trial and programme is cancelled- Derma Sciences Inc.